<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Analyzing bone marrow trephines from (<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients we show for the first time strong over-expression of the DNA methyltransferases 1, and 3A (and 3B to a much lesser extent) in the <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> FAB subtypes refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> (RA) and refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>The increase in <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was much less pronounced in refractory <z:hpo ids='HP_0001903'>anaemia</z:hpo> with ringed sideroblasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Classification according to the new WHO guidelines revealed distinct differences between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>This elevated <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression most probably contributes to the frequently found aberrant hypermethylation in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and might explain the promising clinical response of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients treated with DNMT inhibitors </plain></SENT>
</text></document>